The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).
 
Emily K. Bergsland
Leadership - More Health (I)
Stock and Other Ownership Interests - More Health (I)
Honoraria - UpToDate
Consulting or Advisory Role - Advanced Accelerator Applications; More Health; more health (I)
Research Funding - lexicon (Inst); Merck; Novartis (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Michelle R. Mahoney
No Relationships to Disclose
 
Timothy R. Asmis
No Relationships to Disclose
 
Nathan Hall
No Relationships to Disclose
 
Priya Kumthekar
Leadership - Vivacitas Oncology
Stock and Other Ownership Interests - Vivacitas Oncology
Consulting or Advisory Role - Abbvie
Research Funding - Abbvie; DNAtrix; Genentech/Roche; Novocure; Orbus Therapeutics
Patents, Royalties, Other Intellectual Property - Utility patent for ANG 1005. No financial gain, no royalties.
 
Michael L. Maitland
Consulting or Advisory Role - Bayer (I); Gilead Sciences (I); Merck Sharp & Dohme (I); United Therapeutics (I)
 
Donna Niedzwiecki
No Relationships to Disclose
 
Andrew B. Nixon
Consulting or Advisory Role - Kanghong Pharma; Lilly; Pfizer
Research Funding - Acceleron Pharma; Amgen; AstraZeneca/MedImmune; Eureka Therapeutics; Genentech/Roche; Leadiant Biosciences; medpacto; Novartis; Seagen; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Patent (Inst); Patent Pending (Inst)
Travel, Accommodations, Expenses - TRACON Pharma
 
Eileen Mary O'Reilly
Consulting or Advisory Role - 3DMedcare (I); Agios (I); Alignmed (I); Amgen (I); Antengene (I); Aptus Clinical; Aptus Clinical (I); ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); BeiGene (I); BiolineRx; Boston Scientific (I); Bridgebio (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CARsgen Therapeutics (I); CASI Pharmaceuticals (I); CASI Pharmaceuticals (I); Celgene; Celgene (I); Celsion (I); Cipla (I); CytomX Therapeutics; Daiichi Sankyo (I); Debiopharm Group (I); Delcath Systems (I); Eisai (I); Exelixis (I); Genoscience Pharma (I); Gilead Sciences; Halozyme; Halozyme (I); Hengrui Medicine (I); Inovio Pharmaceuticals (I); Ipsen (I); Janssen; Jazz Pharmaceuticals (I); Kyowa Hakko Kirin (I); LAM Therapeutics (I); Lilly (I); Loxo; Merck (I); Merrimack; Minapharma (I); Newlink Genetics; Novella Clinical (I); Onxeo (I); PCI Biotech (I); Pfizer; Pharmacyclics; Pharmacyte Biotech; Pieris Pharmaceuticals; QED Therapeutics (I); RedHill Biopharma (I); Sanofi; Sanofi (I); Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); SOBI; Targovax; Tekmira (I); twoXAR; twoXAR (I); VAXIMM; Vicus Therapeutics (I); Yakult Pharmaceutical (I); Yakult Pharmaceutical (I); Yiviva (I)
Research Funding - Acta Biologica (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); Mabvax (Inst); OncoQuest (Inst); OncoQuest (Inst); Roche (Inst)
 
Lawrence Howard Schwartz
Consulting or Advisory Role - Novartis; Roche
Research Funding - Daiichi Sankyo (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Millenium Pharamceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Varian Medical Systems
 
Jonathan R. Strosberg
Honoraria - Novartis
Consulting or Advisory Role - Ipsen; Lexicon; Novartis
Speakers' Bureau - Ipsen; Lexicon
Research Funding - Novartis; Pharmacyclics
Travel, Accommodations, Expenses - Advanced Accelerator Applications
 
Jeffrey A. Meyerhardt
Honoraria - Chugai Pharma; Cota Healthcare; Ignyta; Taiho Pharmaceutical
Research Funding - Boston Biomedical (Inst)